CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.
| Revenue (Most Recent Fiscal Year) | $1.14M |
| Net Income (Most Recent Fiscal Year) | $-88.04M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3020.21 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.84 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -15945.17% |
| Net Margin (Trailing 12 Months) | -15945.17% |
| Return on Equity (Trailing 12 Months) | -16.71% |
| Return on Assets (Trailing 12 Months) | -16.24% |
| Current Ratio (Most Recent Fiscal Quarter) | 30.97 |
| Quick Ratio (Most Recent Fiscal Quarter) | 30.97 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.25 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.45 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.41 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.51 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 76.22M |
| Free Float | 70.58M |
| Market Capitalization | $2.00B |
| Average Volume (Last 20 Days) | 1.40M |
| Beta (Past 60 Months) | 1.08 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 26.56% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |